当前位置： SCI文献检索 > Cancer Immunology Research期刊下所有文献 > Escalating regulation of 5T4-specific IFN-γ+ CD4+ T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy.

Escalating regulation of 5T4-specific IFN-γ+ CD4+ T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy.

Abstract：

:The relationship between the adaptive CD4+ T cell response and human cancer is unclear. The oncofetal antigen 5T4 is expressed on many human carcinomas, including colorectal cancer (CRC) cells, but has limited expression on normal tissues. We previously identified anti-5T4 CD4+ T cells in a proportion of CRC patients, and we extended this study to examine whether the quality or quantity of the T cell response reflects tumor stage. An overlapping peptide library spanning 5T4 was used as a target to enumerate cognate IFN-γ+CD4+ T-cells (measured as spot forming cells [SFC]/105 cultured T cells) in peripheral blood-derived lymphocytes following a 12-day in vitro culture period comparing patients pre-operatively (n = 27) to healthy controls (n = 17). Robust 5T4-specific T cell responses were present in 100% of healthy donors. There was a steady loss of T cell responses with advancing tumors with a significant negative correlation from stage I to III (P = 0.008). The predictability of the decline meant < 200 SFC/105 was only found in subjects with stage III CRC. The mechanism of loss of T cell response is independent of HLA-DR type or patient age, but does correspond to increases in Foxp3+ regulatory T cells (Tregs). Using low-dose cyclophosphamide to reduce the proportion of Tregs in vivo resulted in increased anti-5T4 T cell responses in CRC patients. The selective loss of 5T4-specific IFN-γ+CD4+ T cell responses implies a link between tumor stage and antitumor Th1 effector function; depleting Tregs can enhance such responses.

journal_name

Cancer Immunol Res

journal_title

Cancer immunology research

authors

Scurr M,Bloom A,Pembroke T,Srinivasan R,Brown C,Smart K,Bridgeman H,Davies M,Hargest R,Phillips S,Christian A,Hockey T,Gallimore A,Godkin A

doi

10.1158/2326-6066.CIR-13-0035

subject

Has Abstract

pub_date

2013-12-01 00:00:00

issue

6

eissn

2326-6066

issn

2326-6074

journal_volume

1

pub_type

杂志文章

相关文献

Cancer Immunology Research文献大全
  • Sustained Type I Interferon Reinforces NK Cell-Mediated Cancer Immunosurveillance during Chronic Virus Infection.

    abstract：:The importance of natural killer (NK) cells in the early immune response to viral or bacterial infection is well known. However, the phenotype, function, and physiologic role of NK cells during the late stage of persistent viral infection have not been extensively studied. Here, we characterized NK cells in mice persi...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-18-0403

    authors： Oh JH,Kim MJ,Choi SJ,Ban YH,Lee HK,Shin EC,Lee KM,Ha SJ

    更新日期：2019-04-01 00:00:00

  • Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis.

    abstract：:T-cell receptor (TCR) gene therapy is a promising next-generation antitumor treatment. We previously developed a single-T-cell analysis protocol that allows the rapid capture of paired TCRα and β cDNAs. Here, we applied the protocol to analyze the TCR repertoire of tumor-infiltrating lymphocytes (TIL) of various cance...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-17-0489

    authors： Shitaoka K,Hamana H,Kishi H,Hayakawa Y,Kobayashi E,Sukegawa K,Piao X,Lyu F,Nagata T,Sugiyama D,Nishikawa H,Tanemura A,Katayama I,Murahashi M,Takamatsu Y,Tani K,Ozawa T,Muraguchi A

    更新日期：2018-04-01 00:00:00

  • Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.

    abstract：:Despite the rapid progress in the development of novel adoptive T-cell therapies, the clinical benefits in treatment of established tumors have remained modest. Several immune evasion mechanisms hinder T-cell entry into tumors and their activity within the tumor. Of note, oncolytic adenoviruses are intrinsically immun...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-14-0220-T

    authors： Tähtinen S,Grönberg-Vähä-Koskela S,Lumen D,Merisalo-Soikkeli M,Siurala M,Airaksinen AJ,Vähä-Koskela M,Hemminki A

    更新日期：2015-08-01 00:00:00

  • T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells.

    abstract：:MHC-bound peptides from aberrant proteins may be a specific immunotherapeutic target on cancer cells. Because of difficulties in identifying such antigens, viral or model antigens have so far been used to study their biological relevance. We here identify a naturally existing human T-cell epitope derived from a trunca...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-18-0137

    authors： Pont MJ,Oostvogels R,van Bergen CAM,van der Meijden ED,Honders MW,Bliss S,Jongsma MLM,Lokhorst HM,Falkenburg JHF,Mutis T,Griffioen M,Spaapen RM

    更新日期：2019-05-01 00:00:00

  • Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.

    abstract：:Immunotherapy with monoclonal antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) or programmed cell death 1 (PD-1) has improved the survival of patients with metastatic melanoma. These agents carry a certain risk of adverse immune-related events. We present a patient with widely metastatic melanoma who was...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-15-0141

    authors： Maurice C,Schneider R,Kiehl TR,Bavi P,Roehrl MH,Mason WP,Hogg D

    更新日期：2015-12-01 00:00:00

  • Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness.

    abstract：:Advanced and metastatic squamous cell carcinomas (SCC) are common and difficult-to-treat malignancies. We assessed 75 immunotherapy-treated patients with SCC from a clinically annotated database of 2,651 patients, as well as 9,407 patients from a deidentified database for molecular features that might influence checkp...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-18-0716

    authors： Goodman AM,Kato S,Chattopadhyay R,Okamura R,Saunders IM,Montesion M,Frampton GM,Miller VA,Daniels GA,Kurzrock R

    更新日期：2019-06-01 00:00:00

  • Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.

    abstract：:The presence of regulatory T cells (Treg) in solid tumors is known to play a role in patient survival in ovarian cancer and other malignancies. We assessed inherited genetic variations via 749 tag single-nucleotide polymorphisms (SNP) in 25 Treg-associated genes (CD28, CTLA4, FOXP3, IDO1, IL10, IL10RA, IL15, 1L17RA, I...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-13-0136

    authors： Charbonneau B,Moysich KB,Kalli KR,Oberg AL,Vierkant RA,Fogarty ZC,Block MS,Maurer MJ,Goergen KM,Fridley BL,Cunningham JM,Rider DN,Preston C,Hartmann LC,Lawrenson K,Wang C,Tyrer J,Song H,deFazio A,Johnatty SE,Doher

    更新日期：2014-04-01 00:00:00

  • The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

    abstract：:Programmed death 1 (PD-1) and PD ligand 1 (PD-L1) inhibitors have shown activity in metastatic clear cell renal cell carcinoma (ccRCC). Data on the activity of these agents in patients with non-clear cell RCC (nccRCC) or patients with sarcomatoid/rhabdoid differentiation are limited. In this multicenter analysis, we e...

    journal_title：Cancer immunology research

    pub_type： 杂志文章,多中心研究

    doi：10.1158/2326-6066.CIR-17-0475

    authors： McKay RR,Bossé D,Xie W,Wankowicz SAM,Flaifel A,Brandao R,Lalani AA,Martini DJ,Wei XX,Braun DA,Van Allen E,Castellano D,De Velasco G,Wells JC,Heng DY,Fay AP,Schutz FA,Hsu J,Pal SK,Lee JL,Hsieh JJ,Harshman LC,Si

    更新日期：2018-07-01 00:00:00

  • Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma.

    abstract：:In hepatocellular carcinoma (HCC), surgical resection is associated with high recurrence rate, and no effective adjuvant therapy currently exists. We initiated a pilot randomized trial of perioperative immunotherapy with nivolumab and ipilimumab for resectable HCC. Here, we provide an illustrative report of a case tha...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-18-0605

    authors： Kaseb AO,Vence L,Blando J,Yadav SS,Ikoma N,Pestana RC,Vauthey JN,Allison JP,Sharma P

    更新日期：2019-09-01 00:00:00

  • Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer.

    abstract：:Although immune checkpoint blockade (ICB) improves clinical outcome in several types of malignancies, pancreatic ductal adenocarcinoma (PDA) remains refractory to this therapy. Preclinical studies have demonstrated that the relative abundance of suppressive myeloid cells versus cytotoxic T cells determines the efficac...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-19-0661

    authors： Li J,Yuan S,Norgard RJ,Yan F,Yamazoe T,Blanco A,Stanger BZ

    更新日期：2020-03-01 00:00:00

  • STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.

    abstract：:The goal of this study was to characterize the molecular mechanisms underlying cetuximab-mediated upregulation of HLA class I antigen-processing machinery components in head and neck cancer (HNC) cells and to determine the clinical significance of these changes in cetuximab-treated HNC patients. Flow cytometry, signal...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-15-0053

    authors： Srivastava RM,Trivedi S,Concha-Benavente F,Hyun-Bae J,Wang L,Seethala RR,Branstetter BF 4th,Ferrone S,Ferris RL

    更新日期：2015-08-01 00:00:00

  • CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes.

    abstract：:CD137 (4-1BB) costimulation imprints long-term changes that instruct the ultimate behavior of T cells that have previously experienced CD137 ligation. Epigenetic changes could provide a suitable mechanism for these long-term consequences. Genome-wide DNA methylation arrays were carried out on human peripheral blood CD...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-17-0159

    authors： Aznar MA,Labiano S,Diaz-Lagares A,Molina C,Garasa S,Azpilikueta A,Etxeberria I,Sanchez-Paulete AR,Korman AJ,Esteller M,Sandoval J,Melero I

    更新日期：2018-01-01 00:00:00

  • Dietary Consumption of Black Raspberries or Their Anthocyanin Constituents Alters Innate Immune Cell Trafficking in Esophageal Cancer.

    abstract：:Freeze-dried black raspberries (BRB), their component anthocyanins (AC), and a metabolite of BRB ACs, protocatechuic acid (PCA), inhibit the development of esophageal cancer in rats induced by the carcinogen, N-nitrosomethylbenzylamine (NMBA). All three components reduce inflammation in the esophagus and in plasma. Th...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-15-0091

    authors： Peiffer DS,Wang LS,Zimmerman NP,Ransom BW,Carmella SG,Kuo CT,Chen JH,Oshima K,Huang YW,Hecht SS,Stoner GD

    更新日期：2016-01-01 00:00:00

  • The Antigen ASB4 on Cancer Stem Cells Serves as a Target for CTL Immunotherapy of Colorectal Cancer.

    abstract：:Colorectal cancer consists of a small number of cancer stem cells (CSC) and many non-CSCs. Although rare in number, CSCs are a target for cancer therapy, because they survive conventional chemo- and radiotherapies and perpetuate tumor formation in vivo In this study, we conducted an HLA ligandome analysis to survey HL...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-17-0518

    authors： Miyamoto S,Kochin V,Kanaseki T,Hongo A,Tokita S,Kikuchi Y,Takaya A,Hirohashi Y,Tsukahara T,Terui T,Ishitani K,Hata F,Takemasa I,Miyazaki A,Hiratsuka H,Sato N,Torigoe T

    更新日期：2018-03-01 00:00:00

  • Urinary Bladder Cancer Tregs Suppress MMP2 and Potentially Regulate Invasiveness.

    abstract：:Regulatory T cells (Treg) have long been considered one-sided suppressors of antitumor immune responses and hence associated with poor patient outcome in cancer. However, evidence is mounting of a paradoxical positive prognostic effect of Tregs on certain malignancies, including urinary bladder cancer (UBC). This disc...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-17-0466

    authors： Winerdal ME,Krantz D,Hartana CA,Zirakzadeh AA,Linton L,Bergman EA,Rosenblatt R,Vasko J,Alamdari F,Hansson J,Holmström B,Johansson M,Winerdal M,Marits P,Sherif A,Winqvist O

    更新日期：2018-05-01 00:00:00

  • Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers.

    abstract：:Triple-negative breast cancer (TNBC) cells are modulated in reaction to tumor-infiltrating lymphocytes. However, their specific responses to this immune pressure are unknown. In order to address this question, we first used mRNA sequencing to compare the immunophenotype of the TNBC cell line MDA-MB-231 and the luminal...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-16-0182

    authors： Noonepalle SK,Gu F,Lee EJ,Choi JH,Han Q,Kim J,Ouzounova M,Shull AY,Pei L,Hsu PY,Kolhe R,Shi F,Choi J,Chiou K,Huang TH,Korkaya H,Deng L,Xin HB,Huang S,Thangaraju M,Sreekumar A,Ambs S,Tang SC,Munn DH,Shi H

    更新日期：2017-04-01 00:00:00

  • Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow.

    abstract：:Multiple myeloma is characterized by the clonal expansion of malignant plasma cells in the bone marrow. But the phenotypic diversity and the contribution of less predominant B-lineage clones to the biology of this disease have been controversial. Here, we asked whether cells bearing the dominant multiple myeloma immun...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-17-0012

    authors： Hansmann L,Han A,Penter L,Liedtke M,Davis MM

    更新日期：2017-09-01 00:00:00

  • NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.

    abstract：:Solid tumors are refractory to cellular immunotherapies in part because they contain suppressive immune effectors such as myeloid-derived suppressor cells (MDSCs) that inhibit cytotoxic lymphocytes. Strategies to reverse the suppressive tumor microenvironment (TME) should also attract and activate immune effectors wit...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-18-0572

    authors： Parihar R,Rivas C,Huynh M,Omer B,Lapteva N,Metelitsa LS,Gottschalk SM,Rooney CM

    更新日期：2019-03-01 00:00:00

  • Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils.

    abstract：:Myeloid derived suppressor cells (MDSC) are a heterogeneous group of immature cells that accumulate in the peripheral blood and tumor microenvironment and are barriers to cancer therapy. MDSCs serve as prognostic biomarkers and are targets for therapy. On the basis of surface markers, three subsets of MDSCs have been ...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-19-0556

    authors： Khan ANH,Emmons TR,Wong JT,Alqassim E,Singel KL,Mark J,Smith BE,Tario JD,Eng KH,Moysich KB,Odunsi K,Abrams SI,Segal BH

    更新日期：2020-06-01 00:00:00

  • Prognostic Significance of CD169+ Lymph Node Sinus Macrophages in Patients with Malignant Melanoma.

    abstract：:CD169 (sialoadhesin) is a sialic acid receptor that is specifically expressed on macrophages, including lymph node sinus macrophages. Animal studies suggest that CD169(+) macrophages in lymph nodes have properties in preventing cancers. In order to determine the significance of CD169(+) macrophages in patients with ma...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-14-0180

    authors： Saito Y,Ohnishi K,Miyashita A,Nakahara S,Fujiwara Y,Horlad H,Motoshima T,Fukushima S,Jinnin M,Ihn H,Takeya M,Komohara Y

    更新日期：2015-12-01 00:00:00

  • Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.

    abstract：:Pancreatic cancer is a devastating disease that is largely refractory to currently available treatment strategies. Therapeutic resistance is partially attributed to the dense stromal reaction of pancreatic ductal adenocarcinoma tumors that includes a pervasive infiltration of immunosuppressive (M2) macrophages. Nab-pa...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-16-0125

    authors： Cullis J,Siolas D,Avanzi A,Barui S,Maitra A,Bar-Sagi D

    更新日期：2017-03-01 00:00:00

  • Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach.

    abstract：:The "cancer immunogenomics" paradigm has facilitated the search for tumor-specific antigens over the last 4 years by applying comprehensive cancer genomics to tumor antigen discovery. We applied this methodology to identify tumor-specific "neoantigens" in the C57BL/6-derived GL261 and VM/Dk-derived SMA-560 tumor model...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-16-0156

    authors： Johanns TM,Ward JP,Miller CA,Wilson C,Kobayashi DK,Bender D,Fu Y,Alexandrov A,Mardis ER,Artyomov MN,Schreiber RD,Dunn GP

    更新日期：2016-12-01 00:00:00

  • Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade.

    abstract：:Immune checkpoint inhibitors promote T cell-mediated killing of cancer cells; however, only a subset of patients benefit from the treatment. A possible reason for this limitation may be that the tumor microenvironment (TME) is immune privileged, which may exclude cytotoxic T cells from the vicinity of cancer cells. Th...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-16-0303

    authors： Zboralski D,Hoehlig K,Eulberg D,Frömming A,Vater A

    更新日期：2017-11-01 00:00:00

  • Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.

    abstract：:Granulocytic-macrophage colony-stimulating factor (GM-CSF) is used as an adjuvant in cancer vaccine trials and has the potential to enhance antitumor efficacy with immunotherapy; however, its immunologic effects are not fully understood. Here, we report results from a phase I study of neoadjuvant GM-CSF in patients wi...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-16-0042

    authors： Wei XX,Chan S,Kwek S,Lewis J,Dao V,Zhang L,Cooperberg MR,Ryan CJ,Lin AM,Friedlander TW,Rini B,Kane C,Simko JP,Carroll PR,Small EJ,Fong L

    更新日期：2016-11-01 00:00:00

  • Untreated stage IV melanoma patients exhibit abnormal monocyte phenotypes and decreased functional capacity.

    abstract：:Monocytes may contribute to tumor progression in part by mediating tumor-induced immunosuppression. Alterations to the monocyte populations and functions in untreated patients with late-stage melanoma are not fully understood. To characterize these alterations, we compared the frequency, phenotype, and functional capa...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-13-0094

    authors： Chavan R,Salvador D,Gustafson MP,Dietz AB,Nevala W,Markovic SN

    更新日期：2014-03-01 00:00:00

  • Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases.

    abstract：:Delayed radiation-induced vasculitic leukoencephalopathy related to stereotactic radiosurgery (SRS) of brain metastases has been reported to manifest clinically 9 to 18 months after treatment. Immune-modulating therapies have been introduced to treatment regimens for malignancies with metastatic predilection to the br...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-15-0238

    authors： Alomari AK,Cohen J,Vortmeyer AO,Chiang A,Gettinger S,Goldberg S,Kluger HM,Chiang VL

    更新日期：2016-06-01 00:00:00

  • Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia.

    abstract：:Chronic lymphocytic leukemia (CLL) is a B-cell neoplasia characterized by protumor immune dysregulation involving nonmalignant cells of the microenvironment, including T lymphocytes and tumor-associated myeloid cells. Although therapeutic agents have improved treatment options for CLL, many patients still fail to resp...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-19-0152

    authors： Banerjee P,Zhang R,Ivan C,Galletti G,Clise-Dwyer K,Barbaglio F,Scarfò L,Aracil M,Klein C,Wierda W,Plunkett W,Caligaris-Cappio F,Gandhi V,Keating MJ,Bertilaccio MTS

    更新日期：2019-12-01 00:00:00

  • Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.

    abstract：:Efficacious antitumor immune responses must overcome multiple suppressive mechanisms in the tumor microenvironment to control cancer progression. In this study, we demonstrate that dual targeting of suppressive myeloid populations by inhibiting CSF-1/CSF-1R signaling and activation of antigen-presenting cells with ago...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-17-0258

    authors： Wiehagen KR,Girgis NM,Yamada DH,Smith AA,Chan SR,Grewal IS,Quigley M,Verona RI

    更新日期：2017-12-01 00:00:00

  • Integration of Oncogenes via Sleeping Beauty as a Mouse Model of HPV16+ Oral Tumors and Immunologic Control.

    abstract：:Human papillomavirus type 16 (HPV16) is the etiologic factor for cervical cancer and a subset of oropharyngeal cancers. Although several prophylactic HPV vaccines are available, no effective therapeutic strategies to control active HPV diseases exist. Tumor implantation models are traditionally used to study HPV-assoc...

    journal_title：Cancer immunology research

    pub_type： 杂志文章

    doi：10.1158/2326-6066.CIR-16-0358

    authors： Lin YH,Yang MC,Tseng SH,Jiang R,Yang A,Farmer E,Peng S,Henkle T,Chang YN,Hung CF,Wu TC

    更新日期：2018-03-01 00:00:00

  • Translating Science into Survival: Report on the Second International Cancer Immunotherapy Conference.

    abstract：:On September 25-28, 2016, in New York City, the Second International Cancer Immunotherapy Conference was cohosted by the Cancer Research Institute, the American Association for Cancer Research, the Association for Cancer Immunotherapy, and the European Academy of Tumor Immunology. This exciting conference brought toge...

    journal_title：Cancer immunology research

    pub_type：

    doi：10.1158/2326-6066.CIR-16-0276

    authors： Brodsky AN,Hubbard-Lucey VM

    更新日期：2016-12-01 00:00:00